The Differential Effects of Wild-Type and Mutated K-Ras on MST2 Signaling Are Determined by K-Ras Activation Kinetics

REFERENCES

• Barbacid M. 1987. ras genes. Annu. Rev. Biochem. 56:779–827.
   PubMed Web of Science ®Google Scholar
• Downward J. 2003. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3:11–22.
   PubMed Web of Science ®Google Scholar
• Buday L, Downward J. 2008. Many faces of Ras activation. Biochim. Biophys. Acta 1786:178–187.
   PubMed Web of Science ®Google Scholar
• Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Basecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA. 2011. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2:135–164.
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. 2007. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer 7:295–308.
   PubMed Web of Science ®Google Scholar
• Aksamitiene E, Kiyatkin A, Kholodenko BN. 2012. Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem. Soc. Trans. 40:139–146.
   PubMedGoogle Scholar
• Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, Crespo P, Doyle B, Nixon C, Sansom O, Drosten M, Barbacid M, Kolch W. 2011. Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol. Cell 44:893–906.
   PubMedGoogle Scholar
• Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang XF, Dammann R, Pfeifer GP, Avruch J. 2002. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 21:1381–1390.
   PubMedGoogle Scholar
• Agathanggelou A, Cooper WN, Latif F. 2005. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res. 65:3497–3508.
   PubMed Web of Science ®Google Scholar
• Donninger H, Vos MD, Clark GJ. 2007. The RASSF1A tumor suppressor. J. Cell Sci. 120:3163–3172.
   PubMed Web of Science ®Google Scholar
• Yee KS, Grochola L, Hamilton G, Grawenda A, Bond EE, Taubert H, Wurl P, Bond GL, O'Neill E. 2012. A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Res. 72:2206–2217.
   PubMedGoogle Scholar
• Baksh S, Tommasi S, Fenton S, Yu VC, Martins LM, Pfeifer GP, Latif F, Downward J, Neel BG. 2005. The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol. Cell 18:637–650.
   PubMed Web of Science ®Google Scholar
• Vos MD, Dallol A, Eckfeld K, Allen NP, Donninger H, Hesson LB, Calvisi D, Latif F, Clark GJ. 2006. The RASSF1A tumor suppressor activates Bax via MOAP-1. J. Biol. Chem. 281:4557–4563.
   PubMed Web of Science ®Google Scholar
• Avruch J, Praskova M, Ortiz-Vega S, Liu M, Zhang XF. 2006. Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol. 407:290–310.
   PubMedGoogle Scholar
• Guo C, Tommasi S, Liu L, Yee JK, Dammann R, Pfeifer GP. 2007. RASSF1A is part of a complex similar to the Drosophila Hippo/Salvador/Lats tumor-suppressor network. Curr. Biol. 17:700–705.
   PubMed Web of Science ®Google Scholar
• Matallanas D, Romano D, Hamilton G, Kolch W, O'Neill E. 2008. A Hippo in the ointment: MST signalling beyond the fly. Cell Cycle 7:879–884.
   PubMed Web of Science ®Google Scholar
• Mauviel A, Nallet-Staub F, Varelas X. 2012. Integrating developmental signals: a Hippo in the (path)way. Oncogene 31:1743–1756.
   PubMedGoogle Scholar
• Matallanas D, Romano D, Yee K, Meissl K, Kucerova L, Piazzolla D, Baccarini M, Vass JK, Kolch W, O'Neill E. 2007. RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol. Cell 27:962–975.
   PubMed Web of Science ®Google Scholar
• O'Neill E, Rushworth L, Baccarini M, Kolch W. 2004. Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306:2267–2270.
   PubMed Web of Science ®Google Scholar
• Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. 2010. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 24:72–85.
   PubMed Web of Science ®Google Scholar
• Pan D. 2010. The hippo signaling pathway in development and cancer. Dev. Cell 19:491–505.
   PubMed Web of Science ®Google Scholar
• Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, Del Sal G, Levrero M, Blandino G. 2005. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Mol. Cell 18:447–459.
   PubMed Web of Science ®Google Scholar
• Arozarena I, Aaronson DS, Matallanas D, Sanz V, Ajenjo N, Tenbaum SP, Teramoto H, Ighishi T, Zabala JC, Gutkind JS, Crespo P. 2000. The Rho family GTPase Cdc42 regulates the activation of Ras/MAP kinase by the exchange factor Ras-GRF. J. Biol. Chem. 275:26441–26448.
   PubMedGoogle Scholar
• Arozarena I, Matallanas D, Berciano MT, Sanz-Moreno V, Calvo F, Munoz MT, Egea G, Lafarga M, Crespo P. 2004. Activation of H-Ras in the endoplasmic reticulum by the RasGRF family guanine nucleotide exchange factors. Mol. Cell. Biol. 24:1516–1530.
   PubMed Web of Science ®Google Scholar
• Matallanas D, Arozarena I, Berciano MT, Aaronson DS, Pellicer A, Lafarga M, Crespo P. 2003. Differences on the inhibitory specificities of H-Ras, K-Ras, and N-Ras (N17) dominant negative mutants are related to their membrane microlocalization. J. Biol. Chem. 278:4572–4581.
   PubMed Web of Science ®Google Scholar
• Feig LA, Buchsbaum RJ. 2002. Cell signaling: life or death decisions of ras proteins. Curr. Biol. 12:R259–261.
   PubMedGoogle Scholar
• Khokhlatchev A, Rabizadeh S, Xavier R, Nedwidek M, Chen T, Zhang XF, Seed B, Avruch J. 2002. Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12:253–265.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Sabatier C, McCormick F. 2004. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol. Cell. Biol. 24:4943–4954.
   PubMed Web of Science ®Google Scholar
• Stieglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, Khokhlatchev A, Herrmann C. 2008. Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J. 27:1995–2005.
   PubMed Web of Science ®Google Scholar
• Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. 2000. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 275:35669–35672.
   PubMed Web of Science ®Google Scholar
• Creasy CL, Chernoff J. 1995. Cloning and characterization of a member of the MST subfamily of Ste20-like kinases. Gene 167:303–306.
   PubMedGoogle Scholar
• Vavvas D, Li X, Avruch J, Zhang XF. 1998. Identification of Nore1 as a potential Ras effector. J. Biol. Chem. 273:5439–5442.
   PubMed Web of Science ®Google Scholar
• Romano D, Matallanas D, Weitsman G, Preisinger C, Ng T, Kolch W. 2010. Proapoptotic kinase MST2 coordinates signaling crosstalk between RASSF1A, Raf-1, and Akt. Cancer Res. 70:1195–1203.
   PubMedGoogle Scholar
• Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. 2004. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem. J. 381:453–462.
   PubMed Web of Science ®Google Scholar
• Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. 1993. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 260:85–88.
   PubMed Web of Science ®Google Scholar
• Cox AD, Der CJ. 2003. The dark side of Ras: regulation of apoptosis. Oncogene 22:8999–9006.
   PubMed Web of Science ®Google Scholar
• Castellano E, Santos E. 2011. Functional specificity of ras isoforms: so similar but so different. Genes Cancer 2:216–231.
   PubMedGoogle Scholar
• Hamilton M, Wolfman A. 1998. Oncogenic Ha-Ras-dependent mitogen-activated protein kinase activity requires signaling through the epidermal growth factor receptor. J. Biol. Chem. 273:28155–28162.
   PubMed Web of Science ®Google Scholar
• Fotiadou PP, Takahashi C, Rajabi HN, Ewen ME. 2007. Wild-type NRas and KRas perform distinct functions during transformation. Mol. Cell. Biol. 27:6742–6755.
   PubMedGoogle Scholar
• Liao J, Planchon SM, Wolfman JC, Wolfman A. 2006. Growth factor-dependent AKT activation and cell migration requires the function of c-K(B)-Ras versus other cellular ras isoforms. J. Biol. Chem. 281:29730–29738.
   PubMed Web of Science ®Google Scholar
• Jeng HH, Taylor LJ, Bar-Sagi D. 2012. Sos-mediated cross-activation of wild-type Ras by oncogenic Ras is essential for tumorigenesis. Nat. Commun. 3:1168.
   PubMed Web of Science ®Google Scholar
• Young A, Lou D, McCormick F. 2013. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3:112–123.
   PubMed Web of Science ®Google Scholar
• Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. 2003. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 21:3226–3235.
   PubMed Web of Science ®Google Scholar
• Portier M, Moles JP, Mazars GR, Jeanteur P, Bataille R, Klein B, Theillet C. 1992. p53 and RAS gene mutations in multiple myeloma. Oncogene 7:2539–2543.
   PubMed Web of Science ®Google Scholar